Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2022 | AL amyloidosis poster highlights from ISA

Paolo Milani • 7 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Bortezomib Cyclophosphamide Daratumumab Dexamethasone

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, shares his highlights from the AL amyloidosis poster session that took place at this year’s ISA meeting. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Janssen-Cilag

More from Paolo Milani

Doxycycline/TUDCA versus standard supportive therapy in transthyretin cardiac amyloidosis
1:43
Doxycycline/TUDCA versus standard supportive therapy in transthyretin cardiac amyloidosis
Paolo Milani • 28 May 2024
The main goals of therapy in AL amyloidosis
1:23
The main goals of therapy in AL amyloidosis
Paolo Milani • 28 May 2024
Predictors of early mortality in patients with wild-type transthyretin amyloidosis
1:42
Predictors of early mortality in patients with wild-type transthyretin amyloidosis
Paolo Milani • 28 May 2024
Results of the MoRBiDA trial: 18F-PET for the detection of cardiac involvement in AL amyloidosis
1:54
Results of the MoRBiDA trial: 18F-PET for the detection of cardiac involvement in AL amyloidosis
Paolo Milani • 28 May 2024

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Paolo Milani • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Paolo Milani • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Paolo Milani • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Paolo Milani • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals